A class action has been filed against Johnson & Johnson NZ, alleging the company sold and marketed phenylephrine-based cold and flu medicines in New Zealand despite long-standing evidence that the ingredient is ineffective.
Filed by Australia-based JGA Saddler, the lawsuit covers 17 products, including Codral and Sudafed PE, sold over the past 20 years.
The claim, backed by litigation funder Omni Bridgeway, seeks compensation for affected consumers, with JGA Saddler aiming to recruit New Zealand claimants on a “no win, no fee” basis.
Consumer NZ has urged users to join the action and called for the removal of these products from sale. The case follows similar lawsuits in Australia, Canada, and the U.S., while the FDA recently moved to ban phenylephrine as an approved ingredient for oral congestion relief.
Nice
Oh, hard to believe, big pharma lying!!!
And the Jabby jabby?
For goodness sake, one has to be seriously impaired to “think” that there is any utility in patent “cold” remedies.
First there is no such thing as a generalisable “cold” or a contagious obligate intracellular parasite that causes it. This has been established by the British Cold Research Unit over some 40 yrs of research.
Second, there exist multiple sources of potential causes without resorting to intellectual laziness and scratching about for a mythical adeno/ rhino/ para-influenza/ influenza virus “explanation.”
Third and finally, whatever happened to CAVEAT EMPTOR …?!